Your browser doesn't support javascript.
loading
Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.
Panowski, Siler H; Kuo, Tracy C; Zhang, Yi; Chen, Amy; Geng, Tao; Aschenbrenner, Laura; Kamperschroer, Cris; Pascua, Edward; Chen, Wei; Delaria, Kathy; Farias, Santiago; Bateman, Marjorie; Dushin, Russell G; Chin, Sherman M; Van Blarcom, Thomas J; Yeung, Yik Andy; Lindquist, Kevin C; Chunyk, Allison G; Kuang, Bing; Han, Bora; Mirsky, Michael; Pardo, Ingrid; Buetow, Bernard; Martin, Thomas G; Wolf, Jeffrey L; Shelton, David; Rajpal, Arvind; Strop, Pavel; Chaparro-Riggers, Javier; Sasu, Barbra J.
Afiliación
  • Panowski SH; Allogene Therapeutics, Research, South San Francisco, California. siler.panowski@allogene.com javier.chaparro-riggers@pfizer.com barbra.sasu@allogene.com.
  • Kuo TC; ALX Oncology, Biology, South San Francisco, California.
  • Zhang Y; Allogene Therapeutics, Research, South San Francisco, California.
  • Chen A; Pfizer Cancer Immunology Discovery, Pfizer Worldwide Research and Development, South San Francisco, California.
  • Geng T; Pfizer Cancer Immunology Discovery, Pfizer Worldwide Research and Development, South San Francisco, California.
  • Aschenbrenner L; Covance, Inc., Early Phase Development Solutions, Madison, Wisconsin.
  • Kamperschroer C; Drug Safety Research and Development, Pfizer Worldwide Research and Development, Groton, Connecticut.
  • Pascua E; Biomedicine Design, Pfizer Worldwide Research and Development, La Jolla, California.
  • Chen W; Pfizer Cancer Immunology Discovery, Pfizer Worldwide Research and Development, South San Francisco, California.
  • Delaria K; Grifols Diagnostics Solutions, Emeryville, California.
  • Farias S; Cytomx Therapeutics, Process Sciences, South San Francisco, California.
  • Bateman M; Five Prime Therapeutics, Research, South San Francisco, California.
  • Dushin RG; RGD Solutions, LLC, Medicinal Chemistry, Old Lyme, Connecticut.
  • Chin SM; Pfizer Cancer Immunology Discovery, Pfizer Worldwide Research and Development, South San Francisco, California.
  • Van Blarcom TJ; Allogene Therapeutics, Research, South San Francisco, California.
  • Yeung YA; Pfizer Cancer Immunology Discovery, Pfizer Worldwide Research and Development, South San Francisco, California.
  • Lindquist KC; Biomedicine Design, Pfizer Worldwide Research and Development, La Jolla, California.
  • Chunyk AG; Aptevo Therapeutics, Research and Development, Seattle, Washington.
  • Kuang B; Biomedicine Design, Pfizer Worldwide Research and Development, La Jolla, California.
  • Han B; Unity Biotechnology, Safety and DMPK, Brisbane, California.
  • Mirsky M; Drug Safety Research and Development, Pfizer Worldwide Research and Development, Groton, Connecticut.
  • Pardo I; Drug Safety Research and Development, Pfizer Worldwide Research and Development, Groton, Connecticut.
  • Buetow B; Drug Safety Research and Development, Pfizer Worldwide Research and Development, La Jolla, California.
  • Martin TG; Division of Hematology & Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.
  • Wolf JL; Division of Hematology & Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.
  • Shelton D; Pfizer Cancer Immunology Discovery, Pfizer Worldwide Research and Development, South San Francisco, California.
  • Rajpal A; Bristol-Myers Squibb, Discovery Biologics, Redwood City, California.
  • Strop P; Bristol-Myers Squibb, Discovery Biologics, Redwood City, California.
  • Chaparro-Riggers J; Pfizer Cancer Immunology Discovery, Pfizer Worldwide Research and Development, South San Francisco, California. siler.panowski@allogene.com javier.chaparro-riggers@pfizer.com barbra.sasu@allogene.com.
  • Sasu BJ; Allogene Therapeutics, Research, South San Francisco, California. siler.panowski@allogene.com javier.chaparro-riggers@pfizer.com barbra.sasu@allogene.com.
Mol Cancer Ther ; 18(11): 2008-2020, 2019 11.
Article en En | MEDLINE | ID: mdl-31434693
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Complejo CD3 / Anticuerpos Biespecíficos / Inmunoconjugados / Antígeno de Maduración de Linfocitos B / Mieloma Múltiple Tipo de estudio: Prognostic_studies Idioma: En Revista: Mol Cancer Ther Año: 2019 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Complejo CD3 / Anticuerpos Biespecíficos / Inmunoconjugados / Antígeno de Maduración de Linfocitos B / Mieloma Múltiple Tipo de estudio: Prognostic_studies Idioma: En Revista: Mol Cancer Ther Año: 2019 Tipo del documento: Article